Prostate cancer in the older man

ONCOLOGY

Volumn 15, Issue 9, 2001, Pages 1113-1124

  Bubley, Glenn J ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA TOCOPHEROL; ANILIDE; ANTIANDROGEN; ANTINEOPLASTIC AGENT; ANTIOXIDANT; BICALUTAMIDE; MITOXANTRONE; PROSTATE SPECIFIC ANTIGEN; SELENIUM;

AGE; AGED; BLOOD; BRACHYTHERAPY; FAT INTAKE; HUMAN; MALE; METHODOLOGY; MIDDLE AGED; PROSTATE TUMOR; PROSTATECTOMY; REVIEW;

AGE FACTORS; AGED; AGED, 80 AND OVER; ANDROGEN ANTAGONISTS; ANILIDES; ANTINEOPLASTIC AGENTS; ANTIOXIDANTS; BRACHYTHERAPY; DIETARY FATS; HUMANS; MALE; MIDDLE AGED; MITOXANTRONE; PROSTATE-SPECIFIC ANTIGEN; PROSTATECTOMY; PROSTATIC NEOPLASMS; SELENIUM; VITAMIN E;

EID: 0035461548     PISSN: 08909091     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (6)

1. Stanford JL, Stephenson RA, Coyle LM, et al: Prostate Cancer Trends 1973-1995. NIH publication 99-4543; Bethesda, Md; SEER Program, National Cancer Institute; 1999.
2. Scardino FT, Weaver R, Hudson MA: Early detection of prostate cancer. Hum Pathol 23:211-222, 1992.
3. Pienta KJ, Esper PS: Risk factors for prostate cancer. Ann Intern Med 118(10):793-803, 1993.
4. Guileyardo JM, Johnson WD, Welsh RA, et al: Prevalence of latent prostate carcinoma in two US populations. J Natl Cancer Inst 65(2):311316, 1980.
5. Shaneyfelt T, Husein R, Bubley G, et al: Hormonal predictors of prostate cancer: A metaanalysis. J Clin Oncol 18(4): 847-853,2000.
6. Basaria S, Dobs AS: Risks vs benefits of testosterone therapy in elderly men. Drugs Aging 15(2):131-142, 1999.